A Case of SCN5A Mutation-Associated Isolated Left Atrial Standstill and Ischemic Stroke.

A 26-year-old man experienced paroxysmal atrial fibrillation (AF) and cerebral infarction without significant head and neck angiopathy or coagulopathy in April 2020 (Figure 1A and B). The patient has a history of recurrent syncope and was referred to manage a flecainide-resistant paroxysmal AF in July 2020. Electrocardiography and echocardiography revealed PR prolongation (Figure 1C) and progressive disappearance of mitral inflow A-wave (Figure 2), respectively. Other echocardiography parameters are shown in Supplementary Figure 1A and B. The patient underwent an electrophysiological study in March 2021. At a baseline sinus cycle length of 700 ms, the HV interval was 73 ms (Figure 3A). LA pressure was measured at 33 mmHg. Intracardiac echocardiography was performed after trans-sept al puncture (Supplementary Figure 1C). In contrast to the absence of endocardial bipolar voltage signals in the entire LA and pulmonary veins except for a small area at the anteroseptal LA (a bipolar voltage cut-off of 0.1mV, Figure 3B), right atrium (RA) showed relatively preserved voltage with localized scar on the septum in a 3D-electroanatomical map. The intracardiac electrograms showed consistent results (Figure 3A). We performed linear ablations of the superior vena cava to the RA septum and cavotricuspid isthmus without LA ablation. Two months after the procedure, an SCN5A mutation (c.3823G > A[p.Asp1275Asn], likely pathogenic) was found in the proband and his mother and sister (Figure 3C). Paroxysmal complete atrioventricular block was revealed in the Holter during follow-up (Figure 3D). Eventually, the patient underwent a dual-chamber pacemaker implantation eight months after electrophysiology procedure. Our patient had an SCN5A-D1275N mutation associated with isolated LA standstill and progressive AV conduction disease requiring permanent pacemaker implantation.1)2) Although this patient did not show any evidence for ventricular arrhythmia, careful observation and follow-up are warranted for this potentially progressive genetic arrhythmia disease. Written informed consent was obtained from the patient.